Centrum Onkologii Bioinventsp. z o.o.
Research and experimental development on biotechnology
Overview
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2024 – the filing deadline has passed. 6 of 6 financial statements were filed late (the longest delay 696 days for 2021).
- 2024not filed
- 202320/11/2024
- 202210/06/2024
- 202110/06/2024
- 202029/06/2022
- 201931/03/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2023.
Results vs industry
Industry
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 64 | $1,728.80 | 12.8% | |
Tomasz Oczkowskiage 54 | 436 | $11,777.42 | 87.2% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Medycyna Molekularnasp. z o.o. | 2,701.24 USD | 10% |
Bank accounts
Registered as a VAT taxpayer on 2016-12-01.
59 1030 0019 0109 8530 0043 4494
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,399$1,399 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 2, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $55,387$55,387 | Polski Fundusz Rozwoju S.A. | |
| May 22, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Starosta Powiatu Poznań |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| GenxoneS.A. | $665,361.35 | genxone.eu | ||
| Polbiotech Laboratoriumsp. z o.o. | $645,943.81 | polbiotech.pl | ||
| Relvosp. z o.o. | $120,693.26 | relvo.pl | ||
| Microblicsp. z o.o. | $122,383.50 | microblic.pl | ||
| Xenstatssp. z o.o. | $66,774.27 | xenstats.com | ||
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Fungotechsp. z o.o. | $187.68 | fungo.tech | ||
| Dystrogen TherapeuticsS.A. | – | dystrogen.com | ||
| MIMO BiotechP.S.A. | – | mimobiotech.com |
Change history
FAQ
Last updated: 2026-04-22